Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

AUA annual meeting featured the 4 th annual IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Bernard Bochner, with a debate between Drs. Sia ...

AstraZeneca stock rose moderately Tuesday despite a mixed first-quarter report and a setback for its experimental prostate cancer treatment.

AstraZeneca has discontinued its CAPItello-280 phase three trial assessing Truqap, or capivasertib, in combination with docetaxel and androgen-deprivation therapy (ADT) for patients with metastatic ...

Nauseef JT, Sun MP, Thomas C, et al. A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer in patients with prior treatment with ...

Even for patients covered by Medicare, annual out-of-pocket costs for lifesaving cancer treatments taken in pill form have often ...

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, ...

Cancer survivors are banging the gong with gusto at Calgary’s new cancer centre. The outdoor gong reverberates through the ...

Pedro C. Barata, MD, MSc, discusses the use of darolutamide in patients with hormone-sensitive prostate cancer.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on ...

Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 ...

Radiotherapy remains a fundamental treatment for prostate cancer, and recent developments in precision medicine and ...